Table 3.

Summary of the randomized, human placebo-controlled efficacy trials of Gardasil^®

VLP vaccine	Vaccine/placebo group	Vaccine schedule	Duration of trial (months)	Vaccine efficacy (HPV vaccine type) % (95% CI)
HPV 16a	765/768	0, 2, 6	17	100 (90–100)
HPV 6/11/16/18b	277/275	0, 2, 6	35	89 (70–97)
HPV 6/11/16/18c	104/120	0, 2, 6	60	95 (69–100)

^aKoutsky et al (2002).

^bVilla et al (2005).

^cVilla et al (2006).